pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,955 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1213Endpoints919BioPharma Dive354BioSpace340Fierce Biotech317onclive165raps111globenewswire health
therapy area
allOncology8269Rare Disease1942Cardiology1880Immunology1589Hematology1354Vaccines1279Pulmonology
  • STAT seeks reader input on adopting AP’s “healthcare” spelling
    The Associated Press Stylebook recently announced that the term "healthcare" should be written as a single word, updating its long-standing guidance. STAT, which has used the two-word form "health…
    STAT · 4mo agoNeutral↗ source
  • Intellia's single-dose CRISPR therapy cuts hereditary angioedema attacks in Phase 3 trial
    Intellia Therapeutics reported that its gene-editing candidate lonvo-z produced a dramatic reduction in swelling attacks for patients with hereditary angioedema in a Phase 3 study. The single-dose…
    STAT · 4mo agoPositive readoutPositive↗ source
← prev
page 77 of 79
next →
73
fda recalls71
fda medwatch63
fda press38
1277
Psychiatry & CNS895
Ophthalmology521
Pain503
Endocrinology & Metabolism496
Infectious Disease459
  • Intellia’s CRISPR therapy cuts hereditary angioedema attacks by 87% in Phase 3 trial
    Intellia Therapeutics reported that its experimental CRISPR-based drug lonvo-z met the primary endpoint in a Phase 3 study for hereditary angioedema, a rare swelling disorder. The trial showed an…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • Intellia's single-dose CRISPR therapy slashes hereditary angioedema attacks by 87% in Phase 3 trial
    Intellia Therapeutics reported that its CRISPR-based gene editing drug lonvo-z achieved a dramatic reduction in swelling attacks for patients with hereditary angioedema (HAE) in a Phase 3 study. T…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Veradermics reports positive Phase 3 results for oral baldness pill
    Veradermics said its experimental oral formulation of minoxidil met the primary goal of its Phase 3 trial, showing significantly more new hair growth over six months compared with placebo. The dru…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • New U.S. hepatitis B vaccine policy targeting only at-risk newborns could raise infant infections and costs, studies warn
    A new U.S. recommendation limits the birth‑dose hepatitis B vaccine to infants who are judged to be at risk of neonatal infection, rather than offering it universally to all newborns. One study co…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Oruka’s experimental psoriasis drug achieves near-complete skin clearance in Phase 2 trial
    Oruka Therapeutics reported that its experimental IL-23 inhibitor ORKA-001 cleared the skin of 40 of 63 patients (about 63%) in a Phase 2 study, achieving a PASI 100 response at 16 weeks. A further…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion to develop improved JAK inhibitor
    Eli Lilly announced Monday it will purchase Ajax Therapeutics, a biotech based in New York and Cambridge, Massachusetts, in a deal valued at up to $2.3 billion. The transaction includes cash up fr…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Oruka's yearly injectable shows 63% complete clearance in mid-stage psoriasis trial
    Oruka Therapeutics reported results from a Phase 2 trial of its long-acting injectable, ORKA-001, in patients with plaque psoriasis. In the study, 63% of participants achieved complete skin cleara…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Supreme Court split on blocking thousands of Roundup cancer lawsuits
    The Supreme Court heard arguments on Monday about whether to block thousands of lawsuits claiming the weedkiller Roundup caused cancer, and the justices appeared divided. The dispute follows a wav…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Erasca reports early trial shows tumor shrinkage in 40% of pancreatic and 62% of lung cancer patients
    Erasca announced that its experimental RAS-targeting oral drug, ERAS-0015, produced tumor reductions in a portion of patients with advanced pancreatic cancer and advanced non-small cell lung cancer…
    STAT · 4mo agoPositive readoutPositive↗ source
  • FDA greenlights Motif Neurotech's feasibility trial of brain-implant hat for treatment-resistant depression
    The U.S. Food and Drug Administration has approved Motif Neurotech's request to begin an initial feasibility trial of its brain‑implant device aimed at patients with treatment‑resistant depression.…
    STAT · 4mo agoCRLPositive↗ source
  • Trump administration cautions against federal funding for fentanyl test strips and other harm-reduction tools
    The federal agency that oversees addiction and mental health policy sent an open letter to its grant recipients warning them not to spend federal money on harm‑reduction supplies such as sterile sy…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Veradermics reports positive late-stage results for oral hair-loss pill VDPHL01
    Veradermics announced that its experimental oral medication VDPHL01 met its primary goals in a Phase 3 trial for male pattern hair loss. Over six months, participants taking the drug once or twice…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Insider explains the true purpose behind prior authorizations in U.S. health insurance
    The STAT+ newsletter article by Bob Herman reports on an interview with Archelle Georgiou, who previously worked at the nation’s largest health insurer and was involved in efforts to curb prior aut…
    STAT · 4mo agoNeutral↗ source
  • STAT+: Astellas retries XLMTM gene therapy after deaths
    Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news
    STAT · 4mo agoRegulatoryNeutral↗ source
  • GLP-1 drugs and eating disorder risk examined as Covid impact wanes in 2026
    The Morning Rounds newsletter explores the potential link between GLP-1 medications and the development of eating disorders, emphasizing that the risk remains uncertain and warrants further study.…
    STAT · 4mo agoNeutral↗ source
  • CDC-funded hepatitis B vaccine trial in Guinea-Bissau paused amid ethical concerns
    The U.S. Centers for Disease Control and Prevention awarded a $1.6 million grant to a Danish research group to compare hepatitis B vaccination at birth versus at six weeks in infants from Guinea‑Bi…
    STAT · 4mo agoRegulatoryNegative↗ source
  • NIH-funded studies often omit sex-specific results, study finds
    A new analysis of NIH-funded papers reveals that less than half report outcomes separately for men and women. Researchers examined 574 articles published between 2017 and 2024; while 61% included…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Experts say Covid risk has faded, but boosters still advised for vulnerable groups
    Health journalist Helen Branswell reflects on how Covid-19, once the dominant global threat, has receded in public consciousness. Six years after the 2020 lockdowns, mask-wearing and social distanc…
    STAT · 4mo agoNeutral↗ source
  • Mental health clinicians face contracts that charge patients for staying with them
    Sarah Cady, a psychiatric nurse practitioner near New York City, discovered a clause in an employment contract that would require her to pay $7,500 for each patient who chose to continue treatment…
    STAT · 4mo agoNegative↗ source
  • Democrats criticize Health Secretary Kennedy for not releasing vaccine contract
    Senators asked HHS Secretary Robert F. Kennedy Jr. to release a contract with a longtime vaccine critic by a Friday deadline. Kennedy initially said he would be happy to share it, but the deadline…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Integrative medicine doctor Kristine Blanche, wife of acting U.S. attorney general, joins NIH's complementary health advisory council
    Kristine Blanche, an integrative medicine physician and spouse of acting U.S. attorney general Todd Blanche, has been appointed to an NIH advisory council. She will serve on the advisory council f…
    STAT · 4mo agoNeutral↗ source
  • CDC flu research pioneer Nancy Cox dies at 77
    Nancy Cox, a longtime CDC veteran, passed away at age 77 after battling glioblastoma, a form of brain cancer. Cox led the agency's influenza division for 22 years, expanding the team from a modest…
    STAT · 4mo agoNeutral↗ source
  • New Podcast 'Drug Story' Explores the Cultural Impact of Blockbuster Medications
    The First Opinion team has launched a new podcast called “Drug Story,” hosted by journalist and entrepreneur Thomas Goetz. The series aims to uncover the hidden narratives behind widely used medici…
    STAT · 4mo agoPositive↗ source